Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Population preference values for health states in relapsed or refractory B-precursor acute lymphoblastic leukemia in the United Kingdom.

Aristides M, Barlev A, Barber B, Gijsen M, Quinn C.

Health Qual Life Outcomes. 2015 Nov 16;13:181. doi: 10.1186/s12955-015-0377-3.

2.

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.

Cottrell S, Tilden D, Robinson P, Bae J, Arellano J, Edgell E, Aristides M, Boye KS.

Value Health. 2008 May-Jun;11(3):376-88. doi: 10.1111/j.1524-4733.2007.00256.x.

3.

Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer.

Aristides M, Von Der Maase H, Roberts T, Brown A, Kielhorn A, Bhalla S.

Eur J Cancer Care (Engl). 2005 May;14(2):141-2.

PMID:
15842461
4.

Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK.

Aristides M, Lees M, Botwood N, McKendrick J, Stephenson DA, Maniadakis N.

Eur J Health Econ. 2003 Sep;4(3):216-21. Epub 2003 Jul 1.

PMID:
15609188
5.

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.

Le Chevalier T, Scagliotti G, Natale R, Danson S, Rosell R, Stahel R, Thomas P, Rudd RM, Vansteenkiste J, Thatcher N, Manegold C, Pujol JL, van Zandwijk N, Gridelli C, van Meerbeeck JP, Crino L, Brown A, Fitzgerald P, Aristides M, Schiller JH.

Lung Cancer. 2005 Jan;47(1):69-80.

PMID:
15603856
6.

Patient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experiment.

Aristides M, Weston AR, FitzGerald P, Le Reun C, Maniadakis N.

Value Health. 2004 Jul-Aug;7(4):442-54.

7.

Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer.

Robinson P, Maase Hv, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D.

Expert Rev Pharmacoecon Outcomes Res. 2004 Feb;4(1):27-38. doi: 10.1586/14737167.4.1.27.

PMID:
19807333
8.

Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe.

Schiller J, Tilden D, Aristides M, Lees M, Kielhorn A, Maniadakis N, Bhalla S.

Lung Cancer. 2004 Jan;43(1):101-12.

PMID:
14698544
9.
10.
11.

Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.

Lees M, Aristides M, Maniadakis N, McKendrick J, Botwood N, Stephenson D.

Pharmacoeconomics. 2002;20(5):325-37.

PMID:
11994042
12.
13.

Economic impact of increased clinical intervention rates in community pharmacy. A randomised trial of the effect of education and a professional allowance.

Benrimoj SI, Langford JH, Berry G, Collins D, Lauchlan R, Stewart K, Aristides M, Dobson M.

Pharmacoeconomics. 2000 Nov;18(5):459-68.

PMID:
11151399
14.
15.

Murmurs from the heart (or why the stethoscope is not an economic tool)

Aristides M, Gliksman M.

Heart. 1998 Jan;79(1):10-1. No abstract available.

17.

Economic evaluation of insulin lispro versus neutral (regular) insulin therapy using a willingness-to-pay approach.

Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Dobson M.

Pharmacoeconomics. 1998 Mar;13(3):347-58.

PMID:
10178660
18.

Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis.

Davey P, Grainger D, MacMillan J, Rajan N, Aristides M, Gliksman M.

Clin Ther. 1997 Jul-Aug;19(4):656-74.

PMID:
9377611
19.
20.

Applying the Australian guidelines for the reimbursement of pharmaceuticals.

Aristides M, Mitchell A.

Pharmacoeconomics. 1994 Sep;6(3):196-201. No abstract available.

PMID:
10155262
21.

The effects on hospital use and costs of a domiciliary palliative care nursing service.

Aristides M, Shiell A.

Aust Health Rev. 1993;16(4):405-13.

PMID:
10138368

Supplemental Content

Loading ...
Support Center